This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens (NCT00149214), a randomized phase 2 study. The primary outcome is Number of Participants With a Pathological Complete Response.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT00149214 |
| Phase | Phase 2 |
| Condition | Breast Cancer |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None (open label) |
| Enrollment | 257 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Eli Lilly and Company |
| Results posted | Yes |
2. Clinical Question
Population
Female patients with primary, operable breast cancer, described in the registry record as T2-T4/N0-2/M0. The primary-outcome description further refers to participants with a histologic diagnosis of primary operable breast cancer, no concurrent antitumor therapy, a specimen assessed at surgery, and at least one dose of study drug.
Intervention
Doxorubicin plus pemetrexed, followed by docetaxel, as neoadjuvant treatment.
Comparator
Doxorubicin plus cyclophosphamide, followed by docetaxel, as neoadjuvant treatment.
Primary question
How many participants had a pathological complete response after the chemotherapy sequences, assessed using tissue removed at surgery? The registry record does not provide a single primary-outcome comparison between the treatment arms that supports an estimate of the difference.
The clinical question concerns the pathological response to the complete sequential regimens, rather than a comparison of isolated drugs. Both arms include doxorubicin followed by docetaxel; pemetrexed or cyclophosphamide distinguishes the first combination. The registry describes the study as open-label and randomized, and its primary endpoint as a number of participants with pathological complete response. Pathological assessment examines tissue removed during surgery to determine whether tumor tissue is still present after chemotherapy.
The record also names clinical tumor response after the first and second chemotherapy sequences, histologically negative axillary lymph node status at surgery, and disease-free survival as secondary outcomes. Those outcomes address different aspects of response and follow-up; they do not substitute for the primary endpoint. The record does not give a single usable arm-to-arm result for the primary outcome, so the clinical question cannot be answered by an effect estimate from the posted results.
3. Trial Design
This was a randomized, open-label, parallel-group Phase II trial of neoadjuvant treatment for early breast cancer. The registry lists enrollment of 257 participants and describes the population as female patients with primary, operable breast cancer (T2-T4/N0-2/M0). The study is marked completed. The recorded start is 2005-09 and primary completion is 2008-02. Eli Lilly and Company is listed as the sponsor.
One arm received doxorubicin plus pemetrexed followed by docetaxel. The other received doxorubicin plus cyclophosphamide followed by docetaxel. The registry record gives no further detail in the arm descriptions about dose, schedule, treatment modifications, or the precise implementation of each sequence. The primary endpoint timeframe is surgery after eight 21-day cycles of chemotherapy.
Randomization is intended to support a fair comparison by assigning participants to treatment groups through a chance-based process. In a parallel design, each participant is assigned to one treatment group rather than crossing between regimens. The record does not report the randomization method, allocation concealment, or whether the groups were assigned in equal numbers. The equal-allocation assumption described for planning illustrations should not be taken as a description of actual assignment.
Masking is listed as none, so the trial is open-label. Knowledge of assigned treatment can affect care, reporting, and assessment, although pathological assessment of tissue is a distinct endpoint from subjective symptom reporting. The registry record does not say whether pathology assessors were masked. It also does not report a sample-size justification or the planned statistical analysis in enough detail to establish what methods were prespecified.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: The one participant who was randomized to pemetrexed but treated with cyclophosphamide is included in the as randomized group (pemetrexed) for the purposes of the participant flow, excluded from the efficacy analyses (per the protocol), but in the as treated group (cyclophosphamide) for safety analyses.
Overall Study
| Stage | Pemetrexed Plus Doxorubicin, Followed by Docetaxel | Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel |
|---|---|---|
| STARTED | 135 | 122 |
| COMPLETED | 109 | 105 |
| NOT COMPLETED | 26 | 17 |
Reasons for not completing this period:
| Reason | Pemetrexed Plus Doxorubicin, Followed by Docetaxel | Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel |
|---|---|---|
| Adverse Event | 12 | 9 |
| Withdrawal by Subject | 4 | 1 |
| Physician Decision | 3 | 3 |
| Sponsor Decision | 0 | 1 |
| Progressive Disease | 7 | 3 |
Analysis population for the primary outcome, as defined in the registry: Participants meeting the following criteria qualify for pathological tumor response: * Histologic diagnosis of primary operable breast cancer * No concurrent antitumor therapy * Specimen for evaluation of pathological response obtained upon surgery * Treatment with at least one dose of study drug of the assigned study regimen.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Pemetrexed Plus Doxorubicin, Followed by Docetaxel | Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel | Total |
|---|---|---|---|---|
| Participants analysed | 135 | 122 | 257 | |
| Age Continuous | years | 49.9 (SD 10.2) | 49.5 (SD 9.7) | 49.7 (SD 10.0) |
| Sex: Female, Male: Female | Participants | 135 | 122 | 257 |
| Sex: Female, Male: Male | Participants | 0 | 0 | 0 |
| Region of Enrollment: Spain | participants | 36 | 29 | 65 |
| Region of Enrollment: Russian Federation | participants | 14 | 14 | 28 |
| Region of Enrollment: Germany | participants | 74 | 71 | 145 |
| Region of Enrollment: Italy | participants | 11 | 8 | 19 |
| Eastern Cooperative Oncology Group Performance Status: Grade 0 - Fully active | participants | 131 | 113 | 244 |
| Eastern Cooperative Oncology Group Performance Status: Grade 1- Ambulatory; strenuous activity restricted | participants | 1 | 4 | 5 |
| Eastern Cooperative Oncology Group Performance Status: Status Unknown | participants | 3 | 5 | 8 |
| Estrogen and Progesterone Receptor Status: At least one positive | participants | 90 | 78 | 168 |
| Estrogen and Progesterone Receptor Status: Both negative | participants | 45 | 44 | 89 |
| Menopausal Status: Unknown | participants | 0 | 1 | 1 |
| Menopausal Status: Pre-Menopausal | participants | 69 | 66 | 135 |
| Menopausal Status: Peri-Menopausal | participants | 6 | 7 | 13 |
| Menopausal Status: Post-Menopausal | participants | 60 | 48 | 108 |
| Race/Ethnicity: Caucasian | participants | 135 | 119 | 254 |
| Race/Ethnicity: Hispanic | participants | 0 | 3 | 3 |
6. Primary Endpoint
The registry lists the primary outcome as Number of Participants With a Pathological Complete Response, measured over surgery after eight 21-day cycles of chemotherapy.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is the number of participants with a pathological complete response. The registry describes this as a pathological assessment of tissue removed during surgery to determine whether tumor tissue is still present after chemotherapy. Its timeframe is surgery after eight 21-day cycles of chemotherapy. The population description includes a histologic diagnosis of primary operable breast cancer, no concurrent antitumor therapy, a specimen obtained at surgery for assessment, and treatment with at least one dose of study drug.
As a general statistical concept, a pathological endpoint records what is found in tissue rather than relying only on a clinical examination or imaging assessment. It can therefore describe response in the surgical specimen after neoadjuvant treatment. Counting participants meeting the endpoint gives a binary outcome for each eligible participant: the response criterion is either met or not met. A group-level count or proportion can then be compared, if the registry reports the required results and analysis.
The record does not give a single primary-outcome comparison suitable for interpreting the difference between the arms. It indicates that the primary outcome has several categories or time points and is not reduced to one comparison. The record also does not provide the response definition in enough detail to establish every pathology rule used to classify a case. No claim about long-term outcomes follows from the endpoint alone; disease-free survival is listed separately as a secondary outcome.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The posted record establishes the trial question and design, but it does not provide a single primary-outcome result for comparison between the randomized arms. It therefore does not support a quantitative statement about which regimen had more pathological complete responses or about the size or precision of any difference. A count, proportion, effect estimate, confidence interval, and primary-outcome p-value are not reported in a form that allows that comparison to be interpreted.
This distinction matters because a trial description is not itself an outcome result. Randomization describes how treatment assignment was intended to occur; it does not establish the direction, magnitude, or precision of an effect. Likewise, a planned endpoint and a specified assessment time do not reveal how many participants met that endpoint. The available record identifies pathological response at surgery as the primary outcome, but its multiple categories or time points prevent a single comparison from being extracted for interpretation.
The serious adverse event information is descriptive. The record lists 15 affected among 134 at risk in the pemetrexed arm and 25 affected among 123 at risk in the cyclophosphamide arm. These counts should be read alongside their denominators, and they do not by themselves provide an adjusted comparison or a measure of uncertainty. Counts of other adverse events are also listed: 134 among 134 at risk in the pemetrexed arm and 120 among 123 at risk in the cyclophosphamide arm. The registry does not give a statistical comparison for these summaries in the registry record recorded.
General statistical interpretation requires attention to both effect size and precision. An effect estimate describes the observed contrast, while a confidence interval indicates the range of values compatible with the data under the stated method. A p-value addresses compatibility with a specified null hypothesis under a statistical model; it does not measure clinical importance. Since the primary comparison and its uncertainty are not reported, those concepts cannot be applied to a trial-specific efficacy estimate.
The registry record lists secondary outcomes, including clinical response after each chemotherapy sequence, axillary lymph node status at surgery, and disease-free survival. The outcome names alone do not establish their observed results. The record also does not report enough statistical detail to determine how analyses handled missing assessments, multiplicity, or analysis populations. The appropriate conclusion is limited: the registry documents a randomized comparison and its intended endpoint, but the posted information does not provide a single primary result from which to estimate the comparative response.
9. Statistical Methods Explained
General statistical concepts help explain what would be needed to interpret a randomized comparison, but they should not be mistaken for methods documented in this registry record. The record describes randomization, open-label masking status, a parallel design, and a primary pathological response outcome. It does not report the full analysis plan, the randomization procedure, or a single primary-outcome comparison.
What does randomization contribute?
In general, random assignment is used to reduce systematic differences between treatment groups at the point of allocation. It supports a causal comparison when the assignment process is implemented as planned and when follow-up and analysis preserve the comparison. Randomization does not guarantee that every measured or unmeasured characteristic will be balanced, particularly in a study of limited size. The registry record does not describe how the random sequence was generated or how allocation was concealed, so those features cannot be assessed from the record.
What does an open-label design mean?
Open-label means treatment assignment is not masked from participants and relevant study personnel. In general, knowledge of treatment can influence behavior, co-interventions, adverse-event reporting, and clinical assessments. The primary endpoint is based on pathological assessment of tissue removed at surgery, but the record does not say whether the pathologists assessing that tissue were masked to assigned regimen. It is therefore not possible to assess from the registry record whether outcome assessment was protected from knowledge of treatment.
How should a binary endpoint be analyzed?
As a general matter, a participant either meets a defined pathological complete response criterion or does not. A trial report might present the number meeting the criterion and the number assessed in each arm, then estimate a between-arm contrast using a prespecified method. Common contrast measures include a difference in proportions or a relative measure, but no such trial-specific estimate should be inferred without the reported counts and analysis. The registry record describes the endpoint as a number of participants, while also indicating that the outcome is represented by several categories or time points rather than one comparison.
For an estimate to be interpretable, its denominator and analysis population matter. The number randomized, the number treated, the number with tissue assessed, and the number included in a particular analysis can differ. The endpoint description includes eligibility conditions for pathological response, including a specimen obtained at surgery and treatment with at least one dose of study drug. The record does not provide the complete participant flow or the analysis population used for a primary comparison. Those details are not reported in the registry record.
What does a confidence interval add?
In general, a confidence interval communicates uncertainty around an estimated effect under a specified statistical procedure. A narrow interval indicates greater precision than a wide interval, while an interval that includes values on different sides of a null effect may be compatible with a range of interpretations. The interval does not correct bias, resolve missing-data problems, or establish clinical importance. No primary-outcome interval is reported in a single comparison suitable for interpretation in the registry record.
What does a p-value mean?
In general, a p-value describes how unusual the observed data, or data more extreme, would be under a specified null hypothesis and model. It is not the probability that the null hypothesis is true, and it is not a direct measure of the magnitude or importance of a treatment effect. A p-value is most interpretable alongside an effect estimate, a confidence interval, and a prespecified analysis. The record does not provide a single primary-outcome p-value for an arm-to-arm comparison.
How should the planning illustrations be understood?
The planning illustrations are described as calculations based on the observed effect, not as the trial's design justification. Their assumptions are a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation, with the effect to detect expressed as a stated fraction of the observed effect. For non-time-to-event outcomes, the resulting quantities are participants per arm for 80% power or another stated power level; time-to-event illustrations use a total event count. These are planning illustrations, not observed power, and they do not show how many participants were actually enrolled or how the trial was analyzed. The registry does not report the trial's own sample-size justification. Since a single primary effect is not available, the illustrations should not be treated as a substitute for the missing primary comparison.
Over-dispersion is a general concern when observed variability exceeds what a chosen model assumes. For a binary endpoint, the appropriate variance calculation depends on the outcome definition, analysis method, and data structure. A model that understates variability can produce uncertainty estimates that are too narrow. The registry record does not report an over-dispersion model or identify a model-based primary analysis, so no trial-specific conclusion about it is possible.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists pathological complete response as the primary outcome and names clinical tumor response after the first and second chemotherapy sequences, histologically negative axillary lymph node status at surgery, and disease-free survival as secondary outcomes. Several outcomes and assessment points can create multiplicity: when many hypotheses are tested, the chance of at least one apparently notable result can increase. As a general statistical approach, a study may prespecify one primary comparison, use an adjustment for multiple testing, or treat secondary analyses as exploratory. Which approach was planned for this trial is not reported in the registry record.
The primary outcome is not reduced to a single comparison in the posted record because it has several categories or time points. The registry also records two analyses, but does not explain their relationship to the endpoints or identify the analysis method. No adjustment strategy, testing hierarchy, or distinction between confirmatory and exploratory analyses is reported in the registry record.
Missing data can affect a response comparison if participants lack an evaluable surgical specimen or do not meet the stated conditions for pathological assessment. In general, an analysis should clarify which participants were included, how unevaluable cases were handled, and whether sensitivity analyses were used. The record does not report a missing-data method, the extent of missing primary outcome assessments, or a complete analysis-population definition. It also does not describe interim analyses. These omissions prevent assessment of how missingness or repeated testing may have affected the reported results.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Pemetrexed Plus Doxorubicin, Followed by Docetaxel | 15 | 134 | 11.2% |
| Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel | 25 | 123 | 20.3% |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Pemetrexed Plus Doxorubicin, Followed by Docetaxel | 134 of 134 |
| Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel | 120 of 123 |
Most frequent serious adverse event terms
| Event term | Organ system | Pemetrexed Plus Doxorubicin, Followed by Docetaxel | Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel |
|---|---|---|---|
| Leukopenia | Blood and lymphatic system disorders | 4 of 134 | 9 of 123 |
| Febrile neutropenia | Blood and lymphatic system disorders | 4 of 134 | 5 of 123 |
| Pyrexia | General disorders | 3 of 134 | 5 of 123 |
| Neutropenia | Blood and lymphatic system disorders | 1 of 134 | 3 of 123 |
| Vomiting | Gastrointestinal disorders | 3 of 134 | 0 of 123 |
| Diarrhoea | Gastrointestinal disorders | 1 of 134 | 1 of 123 |
| Nausea | Gastrointestinal disorders | 2 of 134 | 0 of 123 |
| Fatigue | General disorders | 0 of 134 | 2 of 123 |
| Mucosal inflammation | General disorders | 0 of 134 | 2 of 123 |
| Appendicitis | Infections and infestations | 0 of 134 | 2 of 123 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Pemetrexed Plus Doxorubicin, Followed by Docetaxel | Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel |
|---|---|---|---|
| Nausea | Gastrointestinal disorders | 82 of 134 | 81 of 123 |
| Alopecia | Skin and subcutaneous tissue disorders | 80 of 134 | 68 of 123 |
| Neutropenia | Blood and lymphatic system disorders | 65 of 134 | 73 of 123 |
| Leukopenia | Blood and lymphatic system disorders | 66 of 134 | 67 of 123 |
| Stomatitis | Gastrointestinal disorders | 53 of 134 | 47 of 123 |
| Fatigue | General disorders | 49 of 134 | 45 of 123 |
| Alanine aminotransferase increased | Investigations | 57 of 134 | 33 of 123 |
| Constipation | Gastrointestinal disorders | 49 of 134 | 35 of 123 |
| Aspartate aminotransferase increased | Investigations | 54 of 134 | 29 of 123 |
| Nail disorder | Skin and subcutaneous tissue disorders | 38 of 134 | 35 of 123 |
Serious events with the highest arm-level rate: leukopenia (7.3%), febrile neutropenia (4.1%), pyrexia (4.1%), neutropenia (2.4%), vomiting (2.2%).
The registry lists serious adverse events for each treatment group with a number at risk and a number affected. In the pemetrexed plus doxorubicin followed by docetaxel group, 15 affected participants are listed among 134 at risk. In the cyclophosphamide plus doxorubicin followed by docetaxel group, 25 are listed among 123 at risk. These are descriptive counts, not a causal or adjusted comparison. They should not be read as a measure of the probability that an individual participant will experience a particular event.
The record lists leukopenia at 7.3%, febrile neutropenia at 4.1%, pyrexia at 4.1%, neutropenia at 2.4%, vomiting at 2.2%, and fatigue at 1.6% among the leading serious adverse event terms. The record does not identify an arm-specific denominator for these term percentages in the information recorded. A participant may also experience more than one event, so event terms need not represent distinct participants.
Other adverse events are listed as 134 affected among 134 at risk in the pemetrexed group and 120 among 123 at risk in the cyclophosphamide group. The record does not provide detail sufficient to interpret these as a severity-specific outcome. Death counts are not reported in the registry record. Differences in exposure duration, event definitions, and follow-up can affect safety comparisons; the registry information stated does not resolve those issues.
12. What the Result Does, and Does Not, Mean
The trial addresses a focused statistical question: whether pathological complete response differed between two sequential neoadjuvant regimens in female patients with primary, operable breast cancer. It documents randomization, an open-label parallel-group design, and surgery after eight 21-day cycles as the primary assessment timeframe. Those details define the intended comparison and endpoint, but they do not establish an observed treatment effect.
The registry record does not provide a single primary-outcome comparison suitable for interpretation. Consequently, it does not support a statement about the direction or magnitude of an arm difference, nor does it establish how precise such a difference would be. Without a reported effect estimate and its uncertainty, a reader cannot determine whether the observed data are compatible with a wide range of effects or a more limited range. No efficacy conclusion should be drawn from the treatment names, design, or endpoint description alone.
The posted safety counts and serious adverse event terms describe recorded events, but are not a complete comparative safety analysis. The affected counts do not by themselves account for differences in exposure or provide a statistical estimate with uncertainty. The event-term percentages have no arm-specific denominator identified in the record. These limitations mean the figures should be understood as descriptive registry summaries.
As a general principle, statistical evidence concerns the data and analysis actually reported, not what a study might have found under another analysis. A result that is absent from the registry record cannot be replaced by a planning calculation, a secondary outcome label, or a count from another safety category. The planning illustrations are not observed power and do not supply missing evidence about the primary outcome. The record supports describing the study question and the available safety summaries, while leaving the comparative pathological response unresolved.
13. Why This Trial Matters Statistically
This trial illustrates why design information and result information need to be read separately. Randomization and a parallel-group structure identify the intended basis for comparison, while the endpoint description identifies what the investigators intended to measure. Neither feature supplies the observed contrast. For a binary response endpoint, interpretation depends on the event counts, denominators, a defined analysis population, and an estimate of uncertainty. The registry record does not provide a single primary-outcome comparison containing those elements.
The trial also highlights the distinction between a clinical endpoint and an analysis-ready outcome. Pathological complete response is described using tissue assessed at surgery, but the registry indicates multiple categories or time points rather than one consolidated comparison. Without a clearly reported endpoint definition and arm-level result, the reader cannot reconstruct the trial's primary inference from the record. A study can have a stated primary outcome while the posted information remains insufficient for a quantitative interpretation of that outcome.
Finally, the record demonstrates why planning illustrations should not be confused with study results. Planning calculations rely on assumptions about effect size, allocation, significance level, and statistical approximation. They can describe hypothetical sample-size requirements, but they do not measure the evidence actually observed. In this trial, the posted illustrations are explicitly planning calculations based on an observed effect, while the primary result is not available as a single comparison. Keeping those roles distinct prevents a planning exercise from being mistaken for an efficacy finding.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The principal limitation for interpreting this trial from the registry record is the absence of a single primary-outcome comparison. The endpoint is named and its surgical assessment timeframe is given, but the record indicates several categories or time points and does not provide one comparison between arms. No arm-level primary response counts, effect estimate, confidence interval, or primary comparison p-value are available in a form that supports a quantitative interpretation.
Important design and analysis details are also not reported in the registry record. These include the randomization procedure, allocation concealment, the full treatment schedules, the pathology assessment rules, whether outcome assessors were masked, the prespecified analysis method, and the primary analysis population. The record does not explain the two analyses it lists, how missing or unevaluable pathology assessments were handled, whether multiplicity was addressed, or whether interim analyses occurred. A sample-size justification for the trial is not reported.
The safety summaries have limits as well. The serious-event counts are descriptive, the serious event term percentages are not accompanied by arm-specific denominators in the registry information stated here, and death counts are not reported. The record does not provide enough information to assess treatment exposure, follow-up differences, or the statistical uncertainty around safety contrasts. These limitations do not negate the documented study design; they constrain what can be concluded from the posted information.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens — NCT00149214.
- Registry record last updated 2012-03-21; status last verified 2012-03.
- Results first posted 2009-05-13.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT00149214 is a completed randomized, open-label, parallel-group Phase II trial sponsored by Eli Lilly and Company. It enrolled 257 participants with breast cancer. The registry describes female patients with primary, operable disease (T2-T4/N0-2/M0) and compares doxorubicin plus pemetrexed followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel.
The primary outcome is the number of participants with pathological complete response, assessed using tissue removed at surgery after eight 21-day cycles of chemotherapy. Secondary outcomes include clinical response after each sequence, axillary lymph node status at surgery, and disease-free survival. The registry record does not provide a single primary-outcome comparison suitable for interpretation. It reports descriptive serious adverse event counts and leading event terms, but does not give a complete comparative safety analysis or report death counts.